Hamburg, Germany – February 20, 2025 – CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and technological capabilities. This strategic initiative will significantly enhance the company’s ability to scale its MAGNET platform, which integrates proprietary SmartSoak® technology with an in-house developed generative AI framework, FragAI, to unlock therapeutic potential for drug targets.

Leveraging its strong financial position, CrystalsFirst is committed to advancing its mission of accelerating drug discovery by unlocking novel chemical matter. With 40+ successful collaborations with leading biotech companies, this expansion will further strengthen its ability to deliver cutting-edge solutions for the drug discovery industry.

“This investment underscores our dedication to pushing the boundaries of structural biology and structurally-enabled drug discovery,” said Dr. Serghei Glinca, CEO of CrystalsFirst. “By enhancing our facilities and technological capabilities, we aim to provide even greater value to our partners and accelerate the development of innovative medicines.”

At its new premises in Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. Operations at the site are set to begin in Q2 2025, marking a major milestone in CrystalsFirst’s growth and ongoing commitment to transforming early-stage drug discovery. 

Media Contact

Dr. Serghei Glinca

CEO, CrystalsFirst GmbH

 serghei.glinca@crystalsfirst.com

+49 6421 968814-0

This press release contains forward-looking statements regarding CrystalsFirst’s expansion plans and anticipated benefits. Actual results may vary due to various factors. CrystalsFirst assumes no obligation to update these statements.